 Silence Therapeutics PLC is to carry out a clinical trial of its pioneering gene silencing therapy SLN124 in a third indication, polycythaemia vera, a rare form of blood cancer. Mark Rothera, chief executive said: We are pleased to report strong progress across both our proprietary and partnered pipelines, including plans to further expand the SLN124 program into a third indication, PV, where endogenous hepcidin modulation can potentially improve outcomes for 3.5 million people worldwide who currently have very limited treatment options. 